Anthony P. Zook
CEO & DirectorMr. Anthony P. Zook, also known as Tony, serves as an Independent Director at Adaptin Bio Operating Corporation since February 2025. He is CEO of NeoGenomics, Inc. from April 1, 2025 and has been its Director since June 26, 2023 and was its Independent Director from June 26, 2023 to April 1, 2025. He serves as Director at NeoGenomics Laboratories, Inc since 2023 and serves as its Chief Executive Officer since April 2025. He serves as Member of Board of Advisors at Laidlaw Venture Partners, LLC since joining the firm on September 21, 2020. He has been Director of ViralClear Pharmaceuticals, Inc. He has a wealth of commercialization experience in the life science industry gained primarily through his career at AstraZeneca Plc. He served as Director at Algorithm Sciences, Inc. since October 2021 until December 2024. He served as an Independent Director of BioSig Technologies, Inc. since July 1, 2020 until April 22, 2022. He served as Chief Executive Officer of Innocoll Holdings plc (formerly known as Innocoll AG) since December 7, 2014 until 2019 and served as its President and Director from March 16, 2017 to 2019. Mr. Zook served as Chairperson of Management Board at Innocoll Holdings plc (formerly known as Innocoll AG) from December 7, 2014 to September 1, 2016 and its Member of Management Board from December 2014 to September 1, 2016. He has extensive pharmaceutical executive management, commercialization and marketing experience. He worked at Innocoll. He served as Chief Executive Officer of VIVUS Inc. from July 2013 to September 2013. He served as an Executive Vice President of Commercial Operations at AstraZeneca plc from January 2010 to January 31, 2013. He is a partner with Lucius Partners. Prior to his extensive consulting work and role as CEO of Innocoll Pharmaceuticals. He is a veteran of the biopharmaceutical industry. He served as Chief Executive Officer of AstraZeneca North America and Executive Vice President of Global Marketing of AstraZeneca Plc since January 2006 November 2008. He served as Director at PhRMA from 2011-2012. He served as President of MedImmune Inc. from November 13, 2008 to February 2010 and served as its Interim Chief Executive Officer and Interim Head. He served as President of MedImmune, LLC since November 2008. He served as President of MedImmune Limited until February 2010. He served as an Interim Head of MedImmune, LLC. He served as Chief Executive Officer and President of AstraZeneca Pharmaceuticals LP. He served as Senior Vice President of Commercial Operations at AstraZeneca Pharmaceuticals LP. He served as an Executive Vice President of North America of AstraZeneca US at AstraZeneca Plc since January 1, 2006, President and Chief Executive Officer from January 1, 2006 to November 2008 and Chief Executive Officer since January 1, 2006. He served as the President of North America of AstraZeneca Plc. He began his sales career in 1983 at Berlex Laboratories, where he held various positions, including District Sales Manager, Marketing Director, Vice President of Commercial Operations, Vice President for National Accounts and then Vice President of Sales. He joined Astra USA in 1997 as its Vice President of Marketing and Sales and then served as Vice President for Sales since 1998. Previously, he served as Vice President for Sales of AstraZeneca. He had been a Director of AltheRx Pharmaceuticals, Inc. from May 2, 2013 until 2014. He is a Member of the Board for First State Innovation. He served as a Director of Inhibikase Therapeutics, Inc. since November 2013. He serves as a Member of the Board for the Pennsylvania Division of the American Cancer Society and a Member of the Executive Council for National Pharmaceutical Council. He serves as a Member of the Board of Trustees for the Healthcare Leadership Council. He served as a Director of VIVUS Inc. from July 2013 to September 2013. He served as a Director of Melinta Therapeutics, Inc. from September 2009 to January 20, 2010. He served or continues to serve on several boards, including Rib-X Pharmaceuticals and Frostburg State University. He earned a B.S. degree in Biology from Frostburg State University and an A.A. degree in chemical engineering from Pennsylvania State University.
Positions
- Company NameNeoGenomics, Inc.Stock CodeNEOPositionCEO & DirectorColleagues
- LALynn A. TetraultIndependent Chair of the Board
- WSWarren StonePresident & COO
- EAElizabeth A. FloegelChief Digital & Information Officer
- GPGary PassmanChief People & Culture Officer
- AJAbhishek JainExecutive VP & CFO
- ALAlison L. HannahMember of Scientific Advisory Board
- SMStephen M. KanovskyIndependent Director
- MAMichael A. KellyIndependent Director
